Kenvue (NYSE:KVUE) Price Target Raised to $21.00

by · The Cerbat Gem

Kenvue (NYSE:KVUE – Free Report) had its price objective increased by Piper Sandler from $20.00 to $21.00 in a report released on Monday, Benzinga reports. They currently have a neutral rating on the stock.

KVUE has been the subject of a number of other reports. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Kenvue from $23.00 to $24.00 and gave the stock a buy rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. increased their price objective on Kenvue from $22.00 to $24.00 and gave the company an overweight rating in a research report on Wednesday, August 7th. Royal Bank of Canada restated an outperform rating and set a $24.00 target price on shares of Kenvue in a research note on Wednesday, August 7th. UBS Group lifted their price target on shares of Kenvue from $20.00 to $22.00 and gave the stock a neutral rating in a research note on Wednesday, August 7th. Finally, Citigroup cut their price objective on Kenvue from $21.00 to $20.00 and set a neutral rating for the company in a report on Wednesday, July 10th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Kenvue has a consensus rating of Hold and a consensus price target of $22.10.

View Our Latest Report on Kenvue

Kenvue Trading Up 0.5 %

NYSE KVUE opened at $23.12 on Monday. Kenvue has a 12 month low of $17.67 and a 12 month high of $23.55. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.69. The stock’s fifty day moving average price is $21.21 and its 200-day moving average price is $20.03. The stock has a market cap of $44.27 billion, a P/E ratio of 29.64, a P/E/G ratio of 2.92 and a beta of 1.40.

Kenvue (NYSE:KVUE – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.28 by $0.04. The company had revenue of $4 billion for the quarter, compared to the consensus estimate of $3.93 billion. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. Kenvue’s revenue for the quarter was down .3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.32 EPS. As a group, equities analysts forecast that Kenvue will post 1.08 EPS for the current fiscal year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th were given a $0.205 dividend. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.55%. The ex-dividend date was Wednesday, August 14th. Kenvue’s dividend payout ratio is presently 105.13%.

Institutional Trading of Kenvue

Institutional investors and hedge funds have recently modified their holdings of the company. Manchester Capital Management LLC boosted its holdings in Kenvue by 80.8% in the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after buying an additional 530 shares during the period. Mather Group LLC. bought a new position in shares of Kenvue in the first quarter worth about $28,000. MV Capital Management Inc. grew its position in shares of Kenvue by 71.2% during the first quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock worth $33,000 after purchasing an additional 642 shares in the last quarter. Salomon & Ludwin LLC bought a new stake in Kenvue during the 1st quarter valued at approximately $33,000. Finally, Riverview Trust Co purchased a new position in Kenvue in the 1st quarter worth approximately $33,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Company Profile

(Get Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Read More